nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ORM1—saliva—conduct disorder	0.149	0.238	CbGeAlD
Gefitinib—SBK1—brain—conduct disorder	0.0494	0.0788	CbGeAlD
Gefitinib—HIPK4—brain—conduct disorder	0.0488	0.0779	CbGeAlD
Gefitinib—CHEK2—brain—conduct disorder	0.043	0.0686	CbGeAlD
Gefitinib—Minaprine—MAOA—conduct disorder	0.0417	0.272	CrCbGaD
Gefitinib—EPHA6—brain—conduct disorder	0.0386	0.0616	CbGeAlD
Gefitinib—MAP3K19—brain—conduct disorder	0.0351	0.056	CbGeAlD
Gefitinib—Iloperidone—DRD4—conduct disorder	0.0327	0.213	CrCbGaD
Gefitinib—EGFR—brain—conduct disorder	0.0284	0.0453	CbGeAlD
Gefitinib—CSNK1E—brain—conduct disorder	0.0273	0.0435	CbGeAlD
Gefitinib—Minaprine—SLC6A4—conduct disorder	0.0269	0.175	CrCbGaD
Gefitinib—IRAK4—brain—conduct disorder	0.0269	0.0428	CbGeAlD
Gefitinib—ERBB3—brain—conduct disorder	0.0263	0.042	CbGeAlD
Gefitinib—IRAK1—brain—conduct disorder	0.025	0.0399	CbGeAlD
Gefitinib—MKNK2—brain—conduct disorder	0.025	0.0399	CbGeAlD
Gefitinib—MKNK1—brain—conduct disorder	0.0247	0.0394	CbGeAlD
Gefitinib—LOC400927-CSNK1E—Melatonin metabolism and effects—MAOA—conduct disorder	0.0237	0.108	CbGpPWpGaD
Gefitinib—Minaprine—HTR2A—conduct disorder	0.0206	0.135	CrCbGaD
Gefitinib—STK10—brain—conduct disorder	0.0204	0.0325	CbGeAlD
Gefitinib—MAP2K5—brain—conduct disorder	0.0182	0.029	CbGeAlD
Gefitinib—Cisapride—HTR2A—conduct disorder	0.0163	0.107	CrCbGaD
Gefitinib—Iloperidone—HTR2A—conduct disorder	0.0151	0.0983	CrCbGaD
Gefitinib—ALB—brain—conduct disorder	0.0129	0.0206	CbGeAlD
Gefitinib—CSNK1E—Melatonin metabolism and effects—MAOA—conduct disorder	0.0125	0.0566	CbGpPWpGaD
Gefitinib—ABCG2—brain—conduct disorder	0.00884	0.0141	CbGeAlD
Gefitinib—CYP1A1—brain—conduct disorder	0.00839	0.0134	CbGeAlD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—SLC6A4—conduct disorder	0.00669	0.0304	CbGpPWpGaD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—DRD4—conduct disorder	0.00629	0.0286	CbGpPWpGaD
Gefitinib—CYP2D6—brain—conduct disorder	0.00606	0.00967	CbGeAlD
Gefitinib—CYP1A1—Estrogen metabolism—COMT—conduct disorder	0.00492	0.0224	CbGpPWpGaD
Gefitinib—CHEK2—FOXM1 transcription factor network—EP300—conduct disorder	0.00467	0.0212	CbGpPWpGaD
Gefitinib—ABCB1—brain—conduct disorder	0.00436	0.00696	CbGeAlD
Gefitinib—LOC400927-CSNK1E—Wnt Signaling Pathway and Pluripotency—EP300—conduct disorder	0.00374	0.017	CbGpPWpGaD
Gefitinib—CHEK2—p53 pathway—EP300—conduct disorder	0.00355	0.0162	CbGpPWpGaD
Gefitinib—CSNK1E—FoxO family signaling—EP300—conduct disorder	0.00353	0.0161	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—SLC6A4—conduct disorder	0.00352	0.016	CbGpPWpGaD
Gefitinib—CYP1A1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00334	0.0152	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—DRD4—conduct disorder	0.00331	0.015	CbGpPWpGaD
Gefitinib—CYP1A1—Oxidative Stress—MAOA—conduct disorder	0.00325	0.0148	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian Clock—EP300—conduct disorder	0.00322	0.0147	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—MB21D1—conduct disorder	0.00315	0.0143	CbGpPWpGaD
Gefitinib—CSNK1E—p53 pathway—EP300—conduct disorder	0.00305	0.0139	CbGpPWpGaD
Gefitinib—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.00273	0.0124	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00255	0.0116	CbGpPWpGaD
Gefitinib—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.00251	0.0114	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—MB21D1—conduct disorder	0.00251	0.0114	CbGpPWpGaD
Gefitinib—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00242	0.011	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—POLR3A—conduct disorder	0.00231	0.0105	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—EP300—conduct disorder	0.00229	0.0104	CbGpPWpGaD
Gefitinib—LOC400927-CSNK1E—Circadian rythm related genes—EP300—conduct disorder	0.00218	0.00989	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MB21D1—conduct disorder	0.00209	0.0095	CbGpPWpGaD
Gefitinib—CSNK1E—Wnt Signaling Pathway and Pluripotency—EP300—conduct disorder	0.00197	0.00894	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—WASF1—conduct disorder	0.00194	0.00884	CbGpPWpGaD
Gefitinib—ABCG2—HIF-2-alpha transcription factor network—EP300—conduct disorder	0.00187	0.00853	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.00185	0.00841	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—POLR3A—conduct disorder	0.00184	0.00838	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MB21D1—conduct disorder	0.00183	0.00834	CbGpPWpGaD
Gefitinib—CSNK1E—G2/M Transition—EP300—conduct disorder	0.00181	0.00824	CbGpPWpGaD
Gefitinib—CSNK1E—Mitotic G2-G2/M phases—EP300—conduct disorder	0.00179	0.00812	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.00178	0.00811	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00168	0.00762	CbGpPWpGaD
Gefitinib—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0016	0.00728	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00158	0.00717	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00158	0.00717	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—WASF1—conduct disorder	0.00155	0.00705	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—POLR3A—conduct disorder	0.00153	0.00697	CbGpPWpGaD
Gefitinib—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00151	0.00688	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MB21D1—conduct disorder	0.00146	0.00665	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MB21D1—conduct disorder	0.0014	0.00635	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00139	0.00631	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—POLR3A—conduct disorder	0.00135	0.00612	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—WASF1—conduct disorder	0.00129	0.00587	CbGpPWpGaD
Gefitinib—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00124	0.00563	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CGA—conduct disorder	0.00123	0.00559	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MB21D1—conduct disorder	0.00122	0.00553	CbGpPWpGaD
Gefitinib—CSNK1E—Circadian rythm related genes—EP300—conduct disorder	0.00114	0.0052	CbGpPWpGaD
Gefitinib—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00114	0.00518	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—WASF1—conduct disorder	0.00113	0.00515	CbGpPWpGaD
Gefitinib—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00113	0.00513	CbGpPWpGaD
Gefitinib—ABCG2—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.0011	0.00501	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—POLR3A—conduct disorder	0.00107	0.00488	CbGpPWpGaD
Gefitinib—CSNK1E—TCF dependent signaling in response to WNT—EP300—conduct disorder	0.00107	0.00487	CbGpPWpGaD
Gefitinib—CSNK1E—RNF mutants show enhanced WNT signaling and proliferation—EP300—conduct disorder	0.00104	0.00471	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—POLR3A—conduct disorder	0.00103	0.00466	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000997	0.00453	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000997	0.00453	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000993	0.00452	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—WASF1—conduct disorder	0.000985	0.00448	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling by WNT in cancer—EP300—conduct disorder	0.000963	0.00438	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CGA—conduct disorder	0.000956	0.00435	CbGpPWpGaD
Gefitinib—EGFR—Androgen receptor signaling pathway—EP300—conduct disorder	0.00093	0.00423	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000907	0.00412	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—WASF1—conduct disorder	0.000903	0.00411	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—POLR3A—conduct disorder	0.000893	0.00406	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000867	0.00394	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—WASF1—conduct disorder	0.000863	0.00392	CbGpPWpGaD
Gefitinib—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000856	0.00389	CbGpPWpGaD
Gefitinib—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.00085	0.00387	CbGpPWpGaD
Gefitinib—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.000845	0.00384	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MB21D1—conduct disorder	0.000814	0.0037	CbGpPWpGaD
Gefitinib—CYP1A1—Biological oxidations—COMT—conduct disorder	0.000809	0.00368	CbGpPWpGaD
Gefitinib—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.000803	0.00365	CbGpPWpGaD
Gefitinib—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.000798	0.00363	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling by Wnt—EP300—conduct disorder	0.000794	0.00361	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—WASF1—conduct disorder	0.000766	0.00348	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CGA—conduct disorder	0.000756	0.00344	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—WASF1—conduct disorder	0.000752	0.00342	CbGpPWpGaD
Gefitinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000744	0.00338	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CGA—conduct disorder	0.000729	0.00331	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—DRD4—conduct disorder	0.000689	0.00313	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000688	0.00313	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CGA—conduct disorder	0.000687	0.00312	CbGpPWpGaD
Gefitinib—CYP2C19—Biological oxidations—COMT—conduct disorder	0.000662	0.00301	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—EP300—conduct disorder	0.00066	0.003	CbGpPWpGaD
Gefitinib—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.000657	0.00299	CbGpPWpGaD
Gefitinib—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.000653	0.00297	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—EP300—conduct disorder	0.000647	0.00294	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000627	0.00285	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000609	0.00277	CbGpPWpGaD
Gefitinib—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000609	0.00277	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CGA—conduct disorder	0.000607	0.00276	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—WASF1—conduct disorder	0.000606	0.00275	CbGpPWpGaD
Gefitinib—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000605	0.00275	CbGpPWpGaD
Gefitinib—CYP2C9—Biological oxidations—COMT—conduct disorder	0.000604	0.00274	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—EP300—conduct disorder	0.000601	0.00273	CbGpPWpGaD
Gefitinib—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000601	0.00273	CbGpPWpGaD
Gefitinib—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.000599	0.00273	CbGpPWpGaD
Gefitinib—EGFR—Immune System—POLR3A—conduct disorder	0.000597	0.00272	CbGpPWpGaD
Gefitinib—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000596	0.00271	CbGpPWpGaD
Gefitinib—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.000595	0.00271	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—WASF1—conduct disorder	0.000584	0.00265	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—EP300—conduct disorder	0.000576	0.00262	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000563	0.00256	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00056	0.00254	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—DRD4—conduct disorder	0.000535	0.00243	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—EP300—conduct disorder	0.000515	0.00234	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000514	0.00234	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000505	0.0023	CbGpPWpGaD
Gefitinib—EGFR—Immune System—WASF1—conduct disorder	0.000503	0.00229	CbGpPWpGaD
Gefitinib—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	0.000496	0.00226	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00049	0.00223	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—WASF1—conduct disorder	0.000486	0.00221	CbGpPWpGaD
Gefitinib—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.000486	0.00221	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—EP300—conduct disorder	0.00047	0.00214	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CGA—conduct disorder	0.000453	0.00206	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HTR2A—conduct disorder	0.000449	0.00204	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—DRD4—conduct disorder	0.000423	0.00192	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—DRD4—conduct disorder	0.000408	0.00186	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CGA—conduct disorder	0.000406	0.00184	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000398	0.00181	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000395	0.0018	CbGpPWpGaD
Gefitinib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000393	0.00179	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—DRD4—conduct disorder	0.000384	0.00175	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—EP300—conduct disorder	0.000375	0.0017	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HTR2A—conduct disorder	0.000349	0.00159	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EP300—conduct disorder	0.00034	0.00155	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—DRD4—conduct disorder	0.00034	0.00154	CbGpPWpGaD
Gefitinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.000335	0.00152	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—WASF1—conduct disorder	0.000325	0.00148	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CGA—conduct disorder	0.000324	0.00148	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EP300—conduct disorder	0.000312	0.00142	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CGA—conduct disorder	0.000307	0.00139	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CGA—conduct disorder	0.000279	0.00127	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HTR2A—conduct disorder	0.000276	0.00126	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EP300—conduct disorder	0.000274	0.00124	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HTR2A—conduct disorder	0.000266	0.00121	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EP300—conduct disorder	0.000264	0.0012	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000255	0.00116	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HTR2A—conduct disorder	0.000251	0.00114	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CGA—conduct disorder	0.000251	0.00114	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CGA—conduct disorder	0.000245	0.00111	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EP300—conduct disorder	0.000238	0.00108	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—EP300—conduct disorder	0.000236	0.00107	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CGA—conduct disorder	0.000231	0.00105	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CGA—conduct disorder	0.000229	0.00104	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—DRD4—conduct disorder	0.000227	0.00103	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HTR2A—conduct disorder	0.000222	0.00101	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EP300—conduct disorder	0.000218	0.000992	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—EP300—conduct disorder	0.000208	0.000948	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—COMT—conduct disorder	0.000204	0.000929	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MAOA—conduct disorder	0.000203	0.000923	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EP300—conduct disorder	0.000201	0.000916	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EP300—conduct disorder	0.000185	0.000842	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EP300—conduct disorder	0.000182	0.000826	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CGA—conduct disorder	0.000151	0.000686	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HTR2A—conduct disorder	0.000148	0.000674	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—COMT—conduct disorder	0.000146	0.000666	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—conduct disorder	0.000146	0.000665	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MAOA—conduct disorder	0.000145	0.000661	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—conduct disorder	0.000141	0.000641	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—COMT—conduct disorder	0.000138	0.000629	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MAOA—conduct disorder	0.000137	0.000625	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—conduct disorder	0.000133	0.000607	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000133	0.000606	CbGpPWpGaD
Gefitinib—ALB—Metabolism—COMT—conduct disorder	0.000126	0.000573	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MAOA—conduct disorder	0.000125	0.000569	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000121	0.000552	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—conduct disorder	0.000121	0.000552	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—conduct disorder	0.000117	0.000534	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—COMT—conduct disorder	0.000113	0.000515	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MAOA—conduct disorder	0.000112	0.000511	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—conduct disorder	0.000112	0.00051	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—COMT—conduct disorder	0.000111	0.000502	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MAOA—conduct disorder	0.00011	0.000499	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000109	0.000496	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—COMT—conduct disorder	0.000104	0.000474	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MAOA—conduct disorder	0.000103	0.00047	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—COMT—conduct disorder	0.000103	0.000469	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MAOA—conduct disorder	0.000103	0.000466	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	9.94e-05	0.000452	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—conduct disorder	8.77e-05	0.000399	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—conduct disorder	7.85e-05	0.000357	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—COMT—conduct disorder	6.81e-05	0.00031	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MAOA—conduct disorder	6.76e-05	0.000307	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—conduct disorder	6.28e-05	0.000286	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—conduct disorder	5.93e-05	0.00027	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—conduct disorder	5.41e-05	0.000246	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—conduct disorder	4.86e-05	0.000221	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—conduct disorder	4.74e-05	0.000215	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—conduct disorder	4.47e-05	0.000203	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—conduct disorder	4.43e-05	0.000201	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—conduct disorder	2.92e-05	0.000133	CbGpPWpGaD
